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Heparin injected into animals  of several species  activates a  powerful lipid 
clearing system in the blood plasma, as was first shown by Hahn (1). The factor 
responsible for clearing  is recognized to be a lipase (2) but despite considerable 
work, recently reviewed by Robinson and French (3, 4), its precise role in the 
physiological processes of fat transport remains uncertain. 
The principal evidence suggesting the functional importance of the clearing 
system is the finding that certain substances which raise the level of blood tri- 
glyceride in vivo also inhibit the cleating system in vitro. Brown (5) and Bragdon 
and Havel (6)  showed that protamine and toluidine blue, long recognized as 
antagonists of the anticoagulant action of heparin, produce raised blood triglye- 
eride levels after injection into rats. Similarly,  2 non-ionic surface active agents, 
triton A 20 and tween 80 whose hyperfipemic effect was described by Kellner 
et al. (7), have also been shown to inhibit this system (8). Recently Rudman and 
Seidman showed that pituitary extracts when injected into rabbits caused de- 
layed hyperlipemia (9). Kellner et al. showed that the extracts alone produced no 
effect on the heparin-activated clearing system in vitro, but plasma from animals 
made hyperlipemic by them was strongly inhibitory (10). 
The purpose of the present publication is to add to the short list of agents 
producing hyperlipemia members of a  distinctly different group of chemical 
substances, the acidic azoproteins. The effects produced depend entirely on the 
particular acidic group present in the azoprotein. For while  the 4-arsonophenyl 
causes a  marked and prolonged hyperlipemia,  2 other groups,  the 4-sulfono- 
phenyl and the 4-carboxyphenyl, produce more complex results consisting of an 
initial raising  and later lowering of the levels of blood triglyceride. It is further 
intended to show that these end results can be related to the effects of the par- 
titular szoprotein on the lipase clearing system, thus providing further evidence 
that  this system has a  significant  role in regulating  blood triglyceride levels. 
*This study was supported by grants from Mr. John W. O'Boyle, the National Cancer 
Institute, and the American Cancer Society. 
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Although azoproteins have been considerably used for antigenic studies since their 
first introduction by Landsteiner more than 40 years ago  (11),  the possibility that 
they might have other biological effects has been largely overlooked. Recently how- 
ever, Kidd found that 4-arsonophenylazoproteins  are strongly inhibitory to proliferat- 
ing  cells  of  a  number  of  transplantable mouse  lymphomas  (12).  Investigations 
of  the  general  biological properties  of  4-arsonophenylazoproteins undertaken  to 
elucidate the cause of this inhibition  showed that they possessed marked anticoagulant 
activity, which  was  to  a  large  extent due  to  complex formation with  fibrinogen, 
producing a  substrate resistant to  the  action of  thrombin (13).  Other acidic azo- 
proteins possessed  similar anticoagulant properties. In the course of these investiga- 
tions the further observation was made that the plasma of animals injected with 4- 
arsonophenylazoproteins became within a few hours markedly lactescent. 
Materials and Metkods 
Preparation of Azoprote/ns.--Diasotates were prepared using standard  methods described 
by Eagle and Vickers (14) and Kidd (12), from the following  substances: arsanilic acid (East- 
man Organic Chemicals, Rochester), p-aminophenylarsene oxide (prepared by reduction of 
arsanilic acid with S(h  according to Ehrlich  and Bertheim,  reference 15), sulfanilic acid, 
p-aminobenzoic acid, and anillue (reagent grades). Bovine albumin (Armour Pharmaceutical 
Company, Kankakee, Illinois, Cohn's fraction V) and human albumin (Merck and Company 
Inc., Rahway, Cohn's fraction V) were used for conjugation. By varying the proportions of 
diazotate and protein in the reaction mixture, azoproteins with different degrees of conjuga- 
tion were obtained, as was shown by analysis for their content of arsenic and of sulfur in 
sulfonic groups (performed by Schwartzkopf Microanalyticai  Laboratories  Inc., Woodside, 
New York). Conjugation was performed usually at pH 9.0 and 0  ° to 4°C. After 2 or more 
hours the pH of the reaction mixture was adjusted to 6.5 and the azoprotein was then freed 
from other reaction products by dialysis against water for 48 hours. The final products were 
lyophilized. 
The degree of conjugation in unsubstituted phenylasoprotein and in 4-carboxyphenylazo- 
protein could not be determined by direct analysis. However, the materials used in the present 
experiments were prepared  using quantities of diazotate  and proteins  equivalent  to those 
which consistently produced 4-arsonophenylazoproteins of 3 to 4 per cent arsenic content, 
that is, using 1 mmole of diazotate per gm of protein and allowing the reaction to proceed to 
completion under the conditions already described. The optical densities at 380 m/~ of 0.01 
gm per cent solutions of these azoproteins in 0.1 ~r phosphate buffer at pH 7.4 were: 4-arsono- 
phenylazoalbumin  (As 3.0 per  cent)  0.244, 4-carboxyphenylazoalbumin 0.386, phenylazo- 
albumin 0.243. 
Animals.--Market bought albino rabbits of both sexes were used, weighing 2.3 to 3.8 kg. 
Azoproteins and other substances were administered to these animals by intravenous  injec- 
tion. Rats were of the Nelson strain  obtained from Carworth Farms I.uc.,  New City, New York, 
and mice were ZBC animals obtained from the late Dr.  J. J. Bittner of the University of 
Minnesota, Minneapolis. 
Blood Samples.--Samples  usually of 1 to 2 ml, but of up to 4.5 ml where analyses of both 
total and trigiyceride lipids were to be performed, were obtained from rabbits by warming the 
ear and cutting a small marginal vessel. They were anticoagulated by mixing 9 parts with 1 of 
isotonic sodium citrate solution. Plasma was separated by centrifugation at 3000 m,~ for 20 
minutes. 
Postheparin plasma (PHP)  was obtained by bleeding rabbits 15 minutes after the intra- j.  D. BROOKE  85 
venous injection of sodium heparin  (Organon Inc., West Orange, New Jersey) in a dosage of 
7.5 mg/kg. 
Lipid Analysis.--Estimations of total plasma lipids were performed according to procedure 
2 or Sperry and Brand  (16). 
Estimations of plasma triglycerides were performed according to Van Handel and Zilver- 
smit (17) using triolein (Mama Research Laboratories Inc., New York) as a standard. 
Plasma Lipid Clearing Activity.--This was measured in  the manner described by Kellner 
e~ a/. (10). Mixtures were prepared containing 0.7 ml PHP or other test plasma, 0.2 ml saline, 
1.0 ml imidazole buffer (0.2 M, pH 7.4) and 0.1 ml of the stabilized coconut oil suspension ediol 
(Schenlab Pharmaceuticals Inc., New York) diluted ~0 in 0.15 M NaCI.  The ediol was added 
last and clearing of the mixture at 37°C was followed from periodic measurements of optical 
density at 7DO m/~ in a Coleman junior spectrophotometer. In testing their effects on the clear- 
ing system, solutions of azoproteins and other substances  (0.02 ml) were added immediately 
before  the ediol. In experiments directly measuring the rate  of hydrolysis of coconut oil, 
ediol diluted ~s  was used in the incubation mixture. 0.5 ml samples were removed initially 
and after 60 or 9Q minutes for determination of their triglyceride contents. 
TABLE I 
Hyperlipemia  Induced  by 4-Arsonophenytazoprotein in Mice and Rate 
Experimental animal 
Mice  1-3 
4-6 
Rats  1-3 
4-6 
Dosage 
mg azo- 
protei~/kg  mg As/kg 
0  0 
615  40.0 
0  0 
308  20.0 
plasma triglyceride  conc. 
Average 
mg per ¢eni 
37.5 
1893.5 
69.8 
2096.2 
Range 
mg. l~er cent 
31.1-44.1 
1606.1-2192.8 
58.7-79.5 
2045.7-2151.4 
Experimental animals (ZBC mice 25 to 30 gm and Nelson strain rats 450 to 500 gin) were 
fasted during the course of the experiment and for the previous 10 hours. Injections of 4- 
arsonophenylazoprotein  (preparation  Mg)  were made intraperitoneally. Mice were killed by 
inhalation of CO2 immediately before bleeding from the posterior vena cava, and rats were 
lightly etherized before cardiac puncture. 
RESULTS 
The Hyperlipemia Produced by 4-Arsonophenylazoprotein.-- When rats and 
mice were injected with quantifies of 4-arsonophenylazoprotein  normally used 
for therapeutic experiments in the treatment of transplanted lymphomas, and 
which caused no external evidence of toxicity, a marked plasma lactescence was 
produced within 2 to 3 hours. As anticipated, this was found to be associated 
with a considerable elevation of the plasma triglyceride level (Table I). 6 hours 
after the injection of azoprotein the triglyceride content of the plasma of 3 mice 
gave an average value of 1894 mg per cent, and of 3 rats 2096 mgper cent. To 86  ACIDIC AZOPROTEINS 
investigate the phenomenon further it was necessary to use animals of a larger 
species in which repeated blood samples could be easily obtained. For this pur- 
pose  the  rabbit proved particularly  suitable.  Lipemia was  readily  and  con- 
sistently produced by quantities of azoprotein which produced no other appar- 
ent toxic effect. 
Table II shows the effect of injections of a mtmber of different 4-arsonophenyl- 
TABLE II 
The Effect of 4-Arsonophenylasoproteins  on the Plasma Triglyceride Concentrations of Rabbits 
Rabbit 
No. 
Treatment 
4-Arsonophenylazoprotein 
used 
None, 
Isotonic NaC1 
None, 
Isotonic NaC1 
Preparation  As 
per cent 
Dosage 
mg ago.. 
protein/kg  As/m[g 
Plasma triglyceride 
cone. 
Before  6 hrs. 
injection  after  injection 
mg  mg 
per ~nt  per cent 
28.3  10.4 
69.4  32.7 
3  Azoalbumin 
4  Azoalbumin 
5  Azoalbumin 
6  Azoalbumin 
7  Azoalbumin 
8  Agoalbumin 
9  Azoalbumin 
10  Azoalbumin 
(human) 
(human) 
(human) 
(human) 
(bovine) 
(human) 
(bovine) 
(human) 
M9 
M9 
M9 
M9 
K9 
K15 
K(4x) 
M8 
6.5 
6.5 
6.5 
6.5 
1.4 
2.2 
5.2 
17.0 
7.7 
15.4 
38.5 
77.0 
357.2 
227.3 
96.4 
29.4 
0.5 
1.0 
2.5 
5.0 
5.0 
5.0 
5.0 
5.0 
38.3 
57.4 
37.1 
40.6 
16.0 
4.4 
5.8 
12.9 
59.0 
249.1 
334.5 
982.8 
280.4 
322.7 
785.1 
275.3 
Albino rabbits (3.0 to 3.7 kg) injected intravenously with solutions of azoproteins in 0.9 
per cent sodium chloride in a volume of 5 to 6 ml. Rabbits 1 and 2 received 0.9 per cent sodium 
chloride solution only. All animals were fasted during the course of the experiment and for the 
preceding 12  hours. 
azoproteins on the plasma triglyceride levels of fasting rabbits. The azoprotein 
preparation M9, which contained 6.5 per cent As, produced in 6 hours a marked 
rise in triglyceride level when given in a dosage of 15 mg/kg, which was equiv- 
alent to 1.0 mg As/kg. Increasing doses produced progressively more powerful 
effects. By contrast, controls injected with physiological saline showed a slightly 
declining plasma triglyceride level during the experiments. 
It will also be seen from Table II that the effectiveness of azoproteins in pro- 
ducing hyperlipemia varied with their arsenic content.  Even though an equal 
amount of arsenic (5.0 mg/kg) was given to each of the animals in this experi- 
ment, conjugates  containing  1.4  and 2.2  per  cent  As  were  considerably  less .I.D.  B~oo~~  87 
effective in influencing blood triglyceride levels than those containing 5.2 and 
6.5 per cent As. But above this, increasing the arsenic content to 17 per cent 
produced  materials  which  in  relation  to  their  arsenic  content  were  again 
considerably less effective. 
Since the 4-arsonophenylazoprotein preparation M9 was the most potent of 
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FIG. 1.  Changes in the plasma triglyceride and total lipid concentrations of a rabbit injec- 
ted with 4-arsonophenylazoprotein  (preparation M9, 5.5 per cent As, dosage 5 nag As/kg). 
those tested, it was used in most of the subsequent experiments. In all 42 rab- 
bits were injected with this azoprotein, in doses containing from 1 to 5  mg 
As/kg, and each showed a marked hyperlipemia. 
Other  experiments,  following the early observations which have been de- 
scribed, revealed further features of the hyperlipemic effect. 
The Rapid Onset of Hyperlipemia.--In  6 rabbits tested, the total fat content 
of the plasma began to rise within 1 hour of the injection of azoprotein. Fig. 1 
shows the results from an animal in which changes in the total fat content 88  ACIDIC AZOPROTEINS 
were examined at intervals for 24 hours. In the 1st hour the fat content rose 
from an initial value of 250 to 420 mg per cent and after this continued to rise 
steeply for  the following 12  hours.  Indeed, it was  still increasing when the 
experiment was ended after 24 hours. At this time, although the animal had been 
fasting since 12 hours before the beginning of the experiment, its plasma was 
extremely lactescent and contained 2225 mg per cent lipid. Examination of the 
plasma samples showed that almost all the increase was due to triglyceride fat. 
A moderate increase of non-triglyceride llpids occurred, which from a preinjec- 
tion level of 205 mg per cent rose to 592 mg per cent at 24 hours, but this was a 
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FIG. 2. Ct~nges in the plasma triglyceride  concentrations of 3 rabbits injected Mth 4-- 
ar~nophenylazoprotein (preparation M9, dosage 5 nag As/kg). 
small change when compared with the massive accumulation of triglyceride 
in the same period. 
Further  experiments showed more of the persistence  of  the  hyperlipemic 
effect. 
The Prolonged Duration  of the ttyperlipemia  Produced by  4-Arsonophenyl- 
azoproteins.--  Fig. 2 shows the result of injecting 3 rabbits with 4-arsonophenyl- 
azoprotein in the dose usually used, that is, 5 mg As/kg. In 2 the hyperlipemic 
effect persisted for 48 hours, while in the 3rd, a less responsive animal, although 
the peak was reached at 9 hours, the level at 24 hours was 175 mg per cent, at 
least twice that found in untreated fasting animals. These results were brought 
about  only  by  the  arsenic-containing  azoproteins,  as  further  experiments 
showed. 
The Failure  of Arsenic-Containing  Substances  Other Than  4-Arsonophenyl- 
azoproteins  to  Produce  Ityperlipemia.--  Following  the  experiments  with  4- 
arsonophenylazoproteins just described, the effects of 4 other arsenic-containing j'.  D.  ~Room~  89 
substances on the blood fat level were examined. First, in an experiment par- 
allel to that shown in Fig.  1, a  mixture of arsanilic acid and human albumin 
both in quantities equivalent to those given in the earlier experiment as azo- 
protein, failed to produce any significant change in either total or triglyceride 
fat levels in the plasma throughout a similar 24 hour period. This may be seen 
in Fig. 3. As the hyperlipemia produced by 4-arsonophenylazoprotein became 
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FIG. 3. The failure of mixtures of arsanilie acid and human albumin to influence  plasma 
triglyceride  concentrations  in the rabbit. A rabbit (weight  3.1 kg) fasting from 12 hours before 
the experiment, was injected with human albumin (72 mg/kg) and arsanilic acid (5 nag As/ 
kg), dissolved  in 6 ml physiological  saline and pH adjusted to 7.3. 
marked soon after its administration  the effect of 3 other arsenicals was ex- 
amined in detail for 24 hours following injection. As shown in Table III, inor- 
ganic arsenic in trivalent or pentavalent form (as sodium arsenite or sodium 
arsenate) failed to influence the blood triglyceride level. Organic arsenic in the 
trivalent form (as mapharsen) similarly was without effect. 
Although 4-arsonophenylazoprotein in a  dose of 5 mg As/kg  produced no 
external evidence of toxicity, other arsenic-containing substances were far more 
toxic and at the doses given  (2 to 3 mg As/kg) 3 out of 6 animals died within 
30 hours. It appears clear, therefore, that the hyperlipemia is not simply a fea- 
ture of arsenic intoxication, but depends on specific structural  features of  the 90  ACIDIC  AZOPROTEINS 
arsenic-containing  azoproteins.  This point will  be  discussed  more fully later, 
in relationship  to  the  activity  of 4-arsonophenylazoproteins  on  the  heparin- 
activated lipase. 
The Effect of 4-Arsonophenylazoprotein in  Vivo on the Activity of tke Heparin- 
Activated  Lipid  Clearing System.--When  heparin  was  given  to  rabbits  which 
had previously received injections of 4-arsonophenylazoprotein, plasma samples 
subsequently  obtained  (PHP)  failed  to  show any lipid  clearing  activity.  An 
TABLE III 
The Failure of Arsenic in a Number of Chemical Combinations to Influence tke Level of Plasma 
Triglyceride in Rabbits 
Rabbit  Arsenical injected  No. 
1  Sodium arsenite 
2  "  " 
3  Sodium arsenate 
4  "  " 
5  Mapharsen 
6 
Dosct 
As/kg 
0 hrs. 
mg per 
cent 
7.7 
23.5 
16.7 
19.4 
48.4 
8.7 
Plasma triglyceride concentrations at intervals after 
the injection of arsenicals 
1 hr. 
mgt~rr 
cent 
7.1 
15.0 
13.3 
14.7 
34.4 
5.4 
3 hrs.  6 hrs. 
mg pet  mg p~ 
cent  cent 
3.3  2.5 
15.9  ~ 14.8 
14.9  15.2 
7.6  7.3 
21.9  26.2 
8.8  6.4 
9 hrs.  12 hrs.  24  hrs. 
rag per ] mg p6r  mg per 
cent__  cent__  cent__ 
13.1  I 28.2  -- 
--  11.3  44.3 
6.1  15.6  26.3 
19.8  25.9 
7.5  12.6 
Plasma samples were obtained from market bought albino rabbits  of either sex, weighing 
2.3 to 2.9 kg, from which food was withheld during the period of the experiment and for the 
preceding  12 hours.  Sodium arsenite  and sodium arsenate  were  dissolved  in  physiological 
saline and the pH adjusted  to 7.2 with 0.15 N NaOH, each animal receiving an injection of 
5  ml.  Mapharsen  (2-amino-4-arsenophenol  hydrochloride,  Parke  Davis  and  Company, 
Detroit)  was injected  in 5 ml distilled water.  The quantities  of arsenic used proved toxic 
to the rabbits.  Rabbit 1 died 9 hours after injection, rabbits 4 and  5  at 24 and 30 hours. 
experiment demonstrating this is shown in Fig. 4. Here PHP was obtained from 
animals which 6 hours previously had been injected with equivalent quantities 
of either 4-arsonophenylazoprotein,  or a  mixture  of arsanilic  acid and human 
albumin,  or  with  physiological saline.  It  will  be  seen  that  the  usual  strong 
clearing action was produced by plasma from the controls which first received 
saline.  So too,  animals  first given a  mixture  of arsanilic  acid with human al- 
bumin produced a  strong plasma  clearing activity.  But plasma from animals 
first  treated  with 4-arsonophenylazoprotein and which was by this  time con- 
siderably lactescent, produced no clearing effect whatsoever. This effect might 
be explained  in one or both of two ways: azoproteins  could prevent  heparin 
from activating the clearing factor or inhibit the formed clearing factor directly. 
The second of these possibilities  was readily tested. j.  D.  ]3Roou~.  91 
Tke Effect of 4-Arsonophenylazoprotein Added in Vitro to the Heparin-Activated 
Clearing  System.--  When  4-arsonophenylazoprotein  was  added  to  PHP,  a 
strong inhibition of the lipid clearing system occurred, as shown in Fig. 5. An 
effect was itemonstrable  at a  concentration in the final mixture as low as 10 
#g of 4-arsonophenylazoprotein/ml which represented only 0.65 #g As/ml. This 
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Fzo. 4. The failure of beparin to bring about activation of the plasma clearing system in 
rabbits previously treated with 4-arsonophenylazoprotein. 
A. Rabbits injected with 5 ml physiological  (phys.) saline 6 hours before injection  of heparin 
(7.5 mg/kg). The graph shows the clearing activity of plasma samples obtained 15 minutes 
later, tested on emulsions of coconut oil. B. As in A, but rabbits injected with 4-arsonophenyl- 
azoprotein (M9, 5 mg As/kg) 6 hours before the injection of heparin. C. As in B, but instead 
of 4-arsonophenylazoprotein, a mixture of arsanilic acid and human albumin (brought to vH 
7.0) was injected. This provided amounts of arsenic and albnrnln  eanal to those ~,iven as azo- 
protein. 
was a  true inhibition of neutral fat hydrolysis,  for when 4-arsonophenylazo- 
protein at a concentration of 0.05 mg/ml was added to 2 clearing systems each 
containing a different sample of PHP, less than 1 per cent of hydrolysis (from 
the initial triglyceride  concentrations of 229.6 and 250.4 mg per  cent)  was 
produced during an incubation period of 60 minutes at 37°C. By contrast, in 
2 controls in which 4-arsonophenylazoprotein  was replaced by bovine albumin, 
55.2 and 43.1 per cent respectively  of the triglyceride  underwent hydrolysis. 
Other arsenlc-containing  substances  failed to produce any notable effect on 
the clearing system. Figs. 6 and 7 show the effects of sodium arsanilate, sodium 92  ACIDIC AZOPROTEINS 
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Fro.  5.  The  inhibition  by  4-arsonophenylazoprotein  of  the  heparin-activated  clearing 
system in ~tro. Concentrations shown are those of the azoprotein M9 in the cleating system. 
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FIG. 6.  The effect of sodium arsenate and arsanih'c acid on the lipid clearing action of PHP 
compared with that of 4-arsonophenylazoprotein. The pH of solutions of each test substance 
was adjusted to 7.3 with 0.15  •  sodium hydroxide before addition to the clearing systems. 
The azoalbumin M4 contained 1.4 per cent As. Concentrations shown in this and succeeding 
figures are of test substances in the total clearing system. 
FIG. 7,  The effect of sodium arsenite on the lipid clearing action of PHP compared with that 
of 4-arsonophenylazoalbumin. J.  D.  BROOm~  93 
arsenate, and sodium arsenite.  Even in concentrations of arsenic many times 
greater  than  that  present  as azoprotein,  they produced only a  minimal  in- 
hibition. 
Overbeek and van der Vies (18) were able to produce a partial inhibition of 
lipid clearing  systems by using concentrations  of sodium arsanilate  of 0.4 to 
3 mg/mi and prolonged incubation with PHP before testing its clearing activity. 
But even under  these conditions, a  concentration of arsanilate  of 0.5 mg/ml 
(which was that used in the present experiments) was only slightly inhibitory. 
It should be noted that  the concentration of arsenic  in this system was 230 
times greater than  that  in others containing  4-arsonophenylazoprotein  which 
were far more powerfully inhibited  (see Fig. 5). 
Since  trivalent  arsenic is a  particularly powerful inhibitor  of a  number of 
sulfhydryl enzymes, several experiments were performed to examine  the possi- 
bility that the presence of a contaminant of arsenic with this valency (perhaps 
formed by reduction during diazotisation) was responsible for inhibition of the 
lipid clearing  system. However, an azoalbumin prepared from p-aminophenyl- 
arsene oxide  (the analogue of p-aminophenylarsonlc acid containing  trivalent 
arsenic),  while  also inhibiting  the clearing  factor in PHP, possessed only 10 
per cent of the activity of the pentavalent arsenic azoprotein (preparation M9) 
when the two were compared by arsenic content. Also, dimercaprol,  L-cysteine, 
and glutathione when incubated with solutions of azoprotein at 50 times the 
molar concentration of arsenic present in these, failed to influence the inhibitory 
action of the 4-arsonophenylazoprotein solutions when they were subsequently 
added to lipid clearing systems. These results indicate that the strong inhibitory 
effect is in fact associated with the  arsonic  group,  that is, with  arsenic  in the 
pentavalent form. 
Since the results described showed that the 4-arsonophenylazoproteins have 
the capacity to inhibit the heparin-activated  clearing  system in ~/tro, experi- 
ments were performed to determine whether inhibition  of this system could 
account for  the different features of the hyperlipemia which were observed 
in ~/vo. 
The  Correlation of  the Hyperlipemia  Induced  by  4-Arsonophenflar,  oprotein 
with Inhibiti,~n of the Heparin-Activated Clearing System.-- A direct comparison 
of the degree of hyperlipemia in serial  plasma  samples  from 4-arsonophenyl- 
azoprotein-treated  animals  with  their inhibitory  action in  heparin-activated 
clearing  systems was examined in 3 rabbits.  Fig.  8 shows the typical result. 
Plasma  samples following  azoprotein  treatment  produced a  considerable in- 
hibition of the clearing  action of PHP, even initially at a  dilution of 1/5. At 
this  dilution  the inhibition  became very slight in samples obtained after  12 
hours,  but undiluted plasma produced a  marked inhibition  for as long as 36 
hours after its administration and even at 48 hours some inhibitory effect was 
still apparent. It will also be seen from the figure that these results corresponded 94  ACIDIC AZOPROTEINS 
well with the degree  of hyperlipemia.  Thus,  the triglyceride level reached its 
maximum at 24 hours and thereafter its declining  values corresponded closely 
to the decreasing  inhibitory activities of the plasma. 
Further experiments were undertaken to determine whether the concentra- 
tion of 4-arsonophenylazoprotein in the plasma of treated animals could be re- 
lated to the degree of hyperlipemia.  Measurements of the rate of clearance of 
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FTO. 8.  The effect of adding plasma samples from a rabbit treated with 4-arsonophenylazo- 
albumin  to heparin-activated  clearing systems.  Plasma samples were obtained at intervals 
from a rabbit injected with 4-arsonophenylazoprotein (M9, 5 nag As/kg). 0.1 ml of each of these 
plasma samples (either undiluted or diluted 1: 5 in physiological saline)  was added to mixtures 
of 0.7 ml PHP, 1.0 ml hnidazole buffer, and 0.2 ml coconut oil emulsion, as in other clearing 
systems. Clearing activities were compared with those of controls in which physiological saline 
replaced the azoprotein-cont~ining plasma. 
*Clearing activity was measured by the decrease in optical density of the test systems (X 
108) during an incubation period of 30 minutes at 37°C. J.  D.  BROOME  95 
4-arsonophenylazoprotein by 2 rabbits (Fig. 9) showed that no azoprotein could 
be detected in the plasma of either animal 24 hours after its administration. 
This finding was confirmed in 4 further animals which at 12 hours all contained 
demonstrable amounts of azoprotein in the plasma, but none by 24 hours. In 
4 of these 6 animals the level of plasma triglyceride was approaching normality 
(90 to 170 mg per cent) at 24 hours and there was no obvious lactescence of the 
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FIG.  9.  Clearance of 4-arsonophenylazoalbumin from the plasma of injected rabbits. 2 
rabbits, weighing 2.9 and 3.1 kg, fasted for 12 hours before  the experiment, were  injected 
intravenously with 4-arsonophenylazoprotein (M9,  dosage  77 mg/kg).  2-ml blood samples 
were obtained before injection and at the intervals shown following it. To measure azoprotein 
concentrations, fat was first extracted by shaking the plasma samples with twice their volume 
of chloroform,  and the optical density of the aqueous phase was measured at 390 m# after 
suitable dilution in 0.1  ~  phosphate buffer pH 7.4.  Preinjection plasma samples similarly 
treated served as blanks. Although other proteins were precipitated by chloroform, control 
experiments showed  the concentration of azoprotein to be not significantly altered by this 
treatment. 
plasma, but in the other two a  high  hyperlipemia persisted for 48 hours (tri- 
glyceride concentrations were then 2050 and 1783 mg per cent respectively). It 
appears,  therefore,  that  although  circulating  azoprotein could be responsible 
for the hyperlipemla during the first 24 hours following injection, other mech- 
anisms must be involved in some animals under  the experimental conditions 
used which prolong the hyperlipemic effect for a considerable period following 
the clearance of azoprotein. 
Whether this late hyperlipemia is an artifact caused by repeated bleeding to 
obtain samples for analysis (19) or is due to an effect of the azoprotein itself, 
remains to be determined. 96  ACIDIC  AZOPROTEINS 
In summary, 4-arsonophenylazoproteins produced a marked elevation in the 
blood levels of triglyceride fat when injected into 3 mammalian species.  In the 
rabbit this was found to be associated with an inhibitory action of the azopro- 
tein on the heparin-activated plasma lipase. But in the experimental systems 
used secondary effects in some animals were found to prolong the hyperlipemia 
after clearance of azoprotein from the plasma. The results differ strikingly from 
those produced by the injection of other acidic azoproteins, as will be described. 
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FIG.  10.  Changes in plasma  triglyceride concentrations following injection of 4-sulfono- 
pbenylazoprotein in rabbits. In both animals a dosage of 77 nag azoprotein/kg was used. 
The Effects of 4-Sulfono-  and 4-Carboxypkenylazoproteins  on Plasma Triglyc- 
eride Concentrations.--  A characteristic sequence of changes in blood triglyceride 
levels occurred when 4-sulfono- and 4-carboxyphenylazoproteins were injected 
into rabbits. Figs. 10 and 11 show the close similarity in the results following 
the injection of both azoproteins.  1 hour following injection, a notable rise in 
triglyceride content occurred,  in  one  case,  following injection of 4-sulfono- 
phenylazoprotein a rise from 9.2 to 185.0 mg per cent was found. But after the 
1st hour a sharp decline was observed, so that in each case at 6 hours the tri- 
glyceride concentration was in the normal fasting range and remained at this 
level until a slight final rise occurred at 24 hours.  With the preparations used j.  D.  BROOm~  97 
the  sulfono derivative produced a  rather  stronger  effect  than  the  carboxy 
derivative.  However,  neither  sulfanilic  acid  nor  p-aminobenzoic  acid,  when 
administered  in greater  or equivalent amounts as a  simple  mixture with pro- 
tein, produced any change in the level of plasma triglyceride.  So too, an azopro- 
tein  which  lacked  acidic  groups  (phenylazoalburnin)  failed  to  produce  any 
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FIG. 11.  Changes in plasma  trigiyceride concentrations following injection of 4-carboxy- 
phenyhzoprotein in rabbits.  Dosages given were:  rabbit  i,  125 mg azoprotein/kg  (----); 
rabbit 2, 100 rag azoprotein/kg  ( .... ); rabbit  3, 77 mg azoprotein/kg  (  ). 
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FIO. 12. Plasma  trigiyceride concentrations  in rabbits  following injection of phenylazo- 
protein. In both experiments shown, a dosage of 200 mg ~oprotein,4r,  g was used. 98  ACIDIC AZOPROTEINS 
significant change  (Fig.  12)  in the early period, although as  with  the acidic 
azoproteins  some  rise  in  the  concentration of  triglyceride occurred after  12 
hours. 
The biphasic nature of the  changes produced by 4-sulfono- and  4-carboxy- 
phenylazoprotein suggested that they might cause several conflicting effects on 
the heparin-activated cleating system. Direct experiments confirmed this. 
Tke  Effects  of  4-Sulfono-  and  4-Carboxypkenylaz~proteins  on  tke  tIeparin- 
Activated Clearing System.-- When 4-sulfono- and 4-carboxyphenylazoproteins 
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Fro. 13. A comparison of the inhibitory activities of 4-arsonophenyl-  and 4-sulfonophenyl- 
azoproteins on the heparin-activated cleating system in v/tTo. 
FIG. 14. A comparison  of the inhibitory activities of 4-arsonophenyI-  and 4-carboxyphenyl- 
azoproteins on the heparin-activated clearing system in ~qtro. 
were  added  to  the  heparin-activated clearing  system in  vitro,  an  inhibitory 
effect was produced. However, as may be seen in Figs.  13 and  14  neither of 
these  substances  acted  so  powerfully as  the  4-arsonophenylazoprotein, for 
although  the preparations of 4-arsonophenylazoprotein and  4-sulfonophenyl- 
azoprotein  possessed  approximately  equivalent  numbers  of  azo  groups  per 
molecule,  x the preparation of 4-sulfonophenylazoprotein possessed only 1/100 
of the inhibitory activity of the 4-arsono derivative. As with arsanilic acid no 
inhibitory activity was shown by simple mixtures of sulfanilic acid or p-amino- 
benzoic acid with serum albumin  (Fig.  15). 
A  correlation between the inhibition of the clearing system and the initial 
hyperlipemia was shown on adding plasma samples obtained 15 minutes after 
aGm atomic weights  of arsenic and sulfonic group sulfur were 0.088 and 0.107 respectively/ 
100 gm azoprotein. j.  D.  BROOXt~  99 
injection of azoprotein to heparin-activated clearing systems. As anticipated, 
these smnples produced an inhibition of the clearing action of PI-IP, but samples 
obtained at 1 hour and later had no such effect, although, as shown by their 
color, a considerable quantity of azoprotein was still present. In complete con- 
trast, these samples themselves produced, like PHP, a strong clearing action  on 
fatty emulsions. 
The Activation of the Plasma Lipid  Clearing System by 4-Sulfono- and 4- 
Carboxyphenylazoproteins.--Figs.  16  and  17  show  that  plasma  samples  ob- 
tained at intervals following the injection of 4-sulfono- and 4-carboxyphenyl- 
azoprotein began to show clearing activity 1 or more hours after administration 
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Fzo. 15. The failure of p-aminobenzoic acid and sulfanilic  acid to inhibit the heparin-ac- 
tivated clearing system  in ~itro.  Sulfanilic  and p-aminobenzoic acid solutions (pH adjusted 
to 7.0) were made up in 8.0 gm per cent bovine serum albumin. 
of azoprotein, which reached its maximum at 3 to 6 hours and afterwards de- 
clined. No clearing action was produced by animals given the non-acidic phenyl- 
azoprotein. 
As with PHP  the clearing activity produced by 4-sulfono- and 4-carboxy- 
phenylazoprotein was associated with the activation of lipase, as may be seen 
in Table IV. The injection of bovine albumin produced no activation of lipase, 
but plasmas  from animals  treated  with 4-sulfono- and 4-carboxyphenylazo- 
proteins were very actively lipolytic, and indeed in some experiments almost as 
strongly as preparations of PHP. 
It is thus seen that under these experimental conditions the changes in plasma 
triglyceride level, both its initial rise and later fall, are closely correlated with 
changes in the activity of the plasma lipid clearing system. 100  ACIDIC AZOPI~OTEINS 
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FIG. 16.  The activation of clearing factor by 4-sulfonophenylazoprotein. A rabbit was in- 
jected with 77 mg/kg of 4-sulfonophenylazoprotein, and plasma samples were obtained at the 
intervals shown.  In clearing systems these samples replaced the PHP used in earlier experi- 
ments. 
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FIG.  17.  The activation of clearing factor by 4-carboxyphenylazoprotein.  A  rabbit  was 
injected with  100 mg/kg of 4-carboxyphenylazoprotein the experiment was otherwise per- 
formed as described in Fig. 15. j.  D.  BROOM~  101 
DISCUSSION 
The experiments described show that 3 azoproteins produce marked effects 
on blood triglyceride levels. 4-Arsonophenylazoprotein produces a high and pro- 
longed  hyperlipemia,  4-sulfono-  and  4-carboxyphenlazoproteins  produce  an 
initial raising and later lowering of blood fat levels. The hyperlipemia consists 
almost entirely of triglyceride;  non-triglyceride  lipids are increased relatively 
little by any of the azoproteins, in this resembling the changes induced in ani- 
mals treated by Kellner et al. with tween 80 and tritons (7). 
To account for the accumulation of fat in the blood of animals treated with 
azoprotein, one must postulate the occurrence of one or both of two processes: 
TABLE  IV 
The Activation of Plasma  Lipase in the Rabbit by 4-Sulfono- and 4-Carboxyphenylazoproteins 
Rabbit 
No.  Substance  injected 
Bovine albumin 
Heparin 
4-Sulfonophenylazoalbumin 
4-Carboxylphenylazoalbumin 
c$ 
Dosage 
~g/kg 
77.0 
7.5 
77.0 
77.0 
77.0 
77.0 
100.0 
100.0 
Lipase activity (triglyce- 
ride fully hydrolyzedin 
90 rain./1 ml plasma) 
Before  Mter 
injection  injection 
mg  mg 
0.25  0.06 
0.17  4.76 
0.21  3.48 
0.26  3.71 
0.17  2.90 
0.00  1.02 
0.00  2.19 
0.00  2.45 
Time after 
injection 
]~r$. 
3 
6 
6 
6 
6 
3 
6 
first, that there is an excessive mobilization of fat from the depots; or, secondly, 
that there is impairment of the removal of fat from the blood, since fat continu- 
ously enters it from the tissues (4). The present experiments provide no evidence 
on whether the first of these mechanisms is involved, but the very close correla- 
tion between changes in triglyceride fat levels and the activity of azoproteins 
on the lipid clearing system does provide evidence for a mechanism by w.hich 
azoproteins  could  act  through  the  second  process  and  so  cause  the  hyper- 
lipemia observed. Recent evidence (Robinson and French, reference 4) suggests 
that the clearing system may, under physiological conditions be located in the 
capillary walls; the effects produced by azoproteins would be fully consistent 
with their acting on such a site. 
On  a  structural  basis,  the  action  of 4-arsono-,  4-sulfono-,  and  4-carboxy- 
phenylazoproteins  on blood fat levels is probably due to their being, llke hep- 
arin,  macromolecules carrying  polar groups with  strong  negative charge;  un- 102  ACIDIC  AZOPROTEINS 
substituted  phenylazoprotein  lacking  the  negative  charge  is  without  ef- 
fect. 
Kom, using  a  lipase  extracted from tissues  which has apparently identical 
properties with that induced by heparin in the plasma,  has provided strong evi- 
dence that  heparin  forms an integral  part of the enzyme molecule  (20,  21). 
In vivo a number of sulfated polysaccharides  can substitute for heparin in acti- 
vating plasma lipase (Constantinides et al., reference 22), and so too can macro- 
molecules with other acidic groups,  as shown by Havel and Bragdon (23). But 
although heparin in low concentration is a potent activator of clearing factor, 
in higher concentration it is in fact strongly inhibitory (24). A possible explana- 
tion for the effects of 4-sulfono- and 4-carboxyphenylazoproteins on the clear- 
ing system may be found by comparison  with these effects of heparin.  Initially, 
following the injections of these 2 azoproteins,  when their concentration in the 
blood is high,  inhibition  of the clearing  system occurs.  But as the azoproteins 
are removed from the blood, their lower concentrations then become such as to 
cause activation  of the clearing  system possibly by acting as substitutes for 
heparin in the lipase molecule. The observed initial  rise and later fall of blood 
triglyceride levels could be explained  on this basis. 
4-Arsonophenylazoproteins  are exceptional  in causing  only inhibition of the 
lipase clearing system and in whatever dose given, no activation of the enzyme. 
The experiments which have now been described do not, however, show the pre- 
cise means of this inhibition,  which, indeed,  is unclear for other inhibitors too. 
It is possible that the protein-combining activity of 4-arsonophenylazoprotein 
is involved (13), either causing complex formation with lipase or inactivation of 
its lipoprotein cofactor (20). However, features of structural similarity between 
4-arsonophenylazoprotein and heparin  (both are macromolecules  with a  high 
negative charge)  suggest that  inhibition  could be caused by displacement of 
heparin from its combination with lipase. There is evidence that pyrophosphate 
and a number of other phosphate compounds inhibit the enzyme activity in this 
way (20). The similarity in charge and other properties between phosphate and 
arsenate groups is shown by their interchangeability in a number of biochemical 
reactions (see, for instance Rothstein, reference  25). 
The results presented thus add 3 further  substances, each an acidic azopro- 
tein, to the list of agents known to produce changes in plasma triglyceride levels. 
It has been possible to correlate the effects  of azoproteins on the lipid clearing 
system with the alterations produced in plasma triglyceride concentrations, pro- 
viding further evidence for the physiological importance of this system. Further 
work may disclose whether the lipid clearing  system is the sole site of action of 
the  acidic  azoproteins  on  the  physiological  mechanisms  controlling  blood 
triglyceride  levels or whether actions on other as yet unrecognized processes are 
also involved. 3.  D.  BgOOM~  103 
SUMMARY 
When injected into the rabbit 3 acidic azoproteins produced marked changes 
in the blood triglyceride levels.  4-Arsonophenylazoproteins, which were found 
to act similarly in 2 other mammalian species, produced a gross and prolonged 
hyperlipemia. 4-sulfono- and 4-carboxyphenylazoproteins in  the  rabbit  pro- 
duced an initial elevation and later lowering in  blood triglyceride levels.  The 
correlation between these changes and the action of the azoproteins on clearing 
factor lipase provides further evidence for the importance of this enzyme in fat 
transport mechanisms. 4-Arsonophenylazoprotein is powerfully  inhibitory to 
the lipase. 4-Carboxy- and 4-sulfonophenylazoprotein in vivo initially inhibit 
the enzyme and later produce a heparin-like activation. 
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